ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Hepatology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

6,497Medicare Part D Prescriptions Filled, Including Refills
$582K Total Retail Price of All Prescriptions
293 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
89% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
METFORMIN HCL 260 165
OMEPRAZOLE 253 177
AMLODIPINE BESYLATE 220 135
SIMVASTATIN 191 122
ATORVASTATIN CALCIUM 157 115
AMLODIPINE BESYLATE-BENAZEPRIL 138 102
DIOVAN HCT 136 116
FLUTICASONE PROPIONATE 132 84
ADVAIR DISKUS 130 68
HYDROCODONE-ACETAMINOPHEN 125 77 S3
LIPITOR 123 91
NASONEX 107 64
NEXIUM 106 57
SPIRIVA 103 79
ZOLPIDEM TARTRATE 99 61
PROAIR HFA 89 39
GLIMEPIRIDE 83 49
GABAPENTIN 79 55
FEXOFENADINE HCL 79 44
TAMSULOSIN HCL 76 59
ALENDRONATE SODIUM 74 55
ENALAPRIL MALEATE 74 40
LEVOTHYROXINE SODIUM 71 38
PLAVIX 71 60
MELOXICAM 69 45
POLYETHYLENE GLYCOL 3350 69 50
CRESTOR 66 60
TRAMADOL HCL 65 46
VOLTAREN 65 39
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 41
CARVEDILOL 62 55
JANUMET 60 36
JANUVIA 59 40
METOPROLOL SUCCINATE 58 30
PROMETHAZINE HCL 58 31 R
GLYBURIDE-METFORMIN HCL 58 51 R
FUROSEMIDE 56 40
CELEBREX 56 35
SINGULAIR 55 32
DIOVAN 54 50
MECLIZINE HCL 51 46
PATANOL 51 40
LIDODERM 50 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.